MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Stephen Johnston(Royal Marsden NHS Foundation Trust), Matthew P. Goetz(Mayo Clinic)
Cited by 673
Related Papers
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|983
Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer
|JAMA Oncology|2019|425
(untitled)
|Edinburgh Research Explorer|0|353